Advertisement

Topics

GSK indicates a return to oncology by appointing Roche veteran

03:45 EST 9 Nov 2017 | Pharmafile

GSK, under its new CEO, has made most of its waves recently not with approvals but with high-profile appointments, and it continued in this trend with the appointment Hal Barron.

The decision to have brought Barron in as Chief Scientific Officer and President, R&D, alongside a position on the board of the company, has already garnered a fair amount of interest. This is mainly down to Barron’s track record with Genentech, as its SVP and CMO, where he brought through a swathe of successful treatments, including Avastin, Tarceva and Perjeta.

read more

Original Article: GSK indicates a return to oncology by appointing Roche veteran

NEXT ARTICLE

More From BioPortfolio on "GSK indicates a return to oncology by appointing Roche veteran"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

GlaxoSmithKline
GlaxoSmithKline is the third largest pharmaceutical company in the world, based on annual sales, which reached $37,134m in 2009. Spread over 100 countries, GSK employs 96,500 people, 13,000 of which are dedicated to research and development of the the ...

Antibodies
An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...